Developer docs
API playgroundTry for free, no card

Search company profiles

CytoVale

Full company profile

uuid00006y4

Namestring
CytoVale
Legal namestring
Cytovale, Inc.
Websiteurl
cytovale.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

CytoVale is a South San Francisco-based medical technology company that develops host-response diagnostics for early detection of immune-mediated diseases, with its commercial focus on sepsis. The company was founded in 2013 and originated in academic research dating to 2007. Its core offering is the IntelliSep Sepsis Test — an FDA 510(k)-cleared in vitro diagnostic that risk-stratifies adult emergency department patients with suspected infection for probability of sepsis with organ dysfunction within three days — paired with the Cytovale System benchtop analyzer.

The IntelliSep test runs on proprietary deformability cytometry technology: a label-free approach in which a standard 100µL blood sample is processed through microfluidic channels, individual white blood cells are interrogated by ultra-high-resolution imaging and computer vision at hundreds of thousands of frames per second, and proprietary machine-learning models translate measured biomechanical features (size, deformability, stiffness, elongation, granularity, nuclear mechanics) into an IntelliSep Index score between 0.1 and 10.0, stratified into three risk bands. Results are delivered in approximately 8 minutes, with a reported 97.5-98% negative predictive value for ruling out sepsis, and the system integrates with existing hospital laboratory workflows via Ethernet to the LIS with no internet connectivity required. Real-world implementations have reported mortality reductions of 19-42% and material improvements in ED throughput and blood culture stewardship.

CytoVale sells through a direct enterprise field-sales motion targeting U.S. hospital emergency departments and laboratories, using a structured protocolized implementation program of discovery, implementation, and reassessment. Revenue is generated through placement of the Cytovale System analyzer and recurring sales of IntelliSep test cartridges (single-use), QC kits, and reagents. The company is privately held, backed primarily by Norwest Venture Partners (lead in both Series C and Series D), Sands Capital, Global Health Investment Corporation, and Breakout Ventures, with total disclosed funding of approximately $184 million across Series C ($84M, November 2023) and Series D ($100M, October 2024).

Short descriptiontext

CytoVale is a medical technology company that developed IntelliSep, an FDA-cleared ~8-minute host-response sepsis diagnostic on its proprietary deformability cytometry analyzer, sold through enterprise field sales to U.S. hospital emergency departments and clinical laboratories.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSouth San Francisco, United States
HQ citystring
South San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sepsis diagnostic test, rapid sepsis detection, host response diagnostics, emergency department diagnostics, deformability cytometry analyzer
Industry2 codes
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAEAF
Microbiology & Infectious Disease Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
Sepsis Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1IntelliSep Sepsis Test Kits and Reagents
TypeHardware Sales
Description

Cytovale generates revenue through the sale of its IntelliSep test cartridges (single-use), QC kits, and related reagents to hospital laboratories. The test uses 100µL from a standard purple-top K2 EDTA blood collection tube. Reagent and consumable sales are recurring as hospitals perform tests on patients presenting to EDs with suspected sepsis.

ghicfunds.org
2Cytovale System Placement
TypeHardware Sales
Description

The company places its Cytovale System analyzer in hospital laboratories. Revenue is generated through associated consumables and reagents consumed with each test. The system is provided as part of the commercial relationship with health systems implementing IntelliSep.

cytovale.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cytovale develops and sells IntelliSep, an FDA-cleared in vitro diagnostic test that runs on the proprietary Cytovale System benchtop analyzer to risk-stratify adult emergency department patients with signs of infection based on probability of sepsis within 3 days, delivering results in approximately 8 minutes using deformability cytometry. Revenue is generated through placement of the Cytovale System analyzer in hospital laboratories and recurring sales of IntelliSep single-use test cartridges and reagents to U.S. hospitals and health systems.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 12 values shown
  • 39% relative risk reduction in 30-day sepsis-associated mortality
+11 more records
Product overview1 text field

CytoVale offers a unified portfolio centered on the IntelliSep sepsis diagnostic test and the Cytovale System medical device. The Cytovale System is the hardware platform that runs the IntelliSep test by isolating, imaging, and analyzing white blood cells via deformability cytometry, computer vision, and machine learning. IntelliSep is the single FDA-cleared in vitro diagnostic application that generates a sepsis probability score (0.1–10.0) stratified into three risk bands in approximately 8 minutes from a 100µL blood sample. IntelliSep operates exclusively on the Cytovale System, making it a tightly coupled platform-and-assay offering rather than a modular add-on architecture.

Product and service2 records
1IntelliSep Sepsis Test
CategoryIn Vitro Diagnostic Test
Description

An FDA-cleared in vitro diagnostic test that risk-stratifies adult emergency department patients with signs and symptoms of infection based on probability of developing sepsis with organ dysfunction within 3 days. Delivers results in approximately 8 minutes using deformability cytometry to analyze biophysical properties of white blood cells, generating a score from 0.1-10.0 stratified into three discrete bands indicating probability of sepsis.

2Cytovale System Analyzer
CategoryMedical Device Platform
Description

A benchtop laboratory analyzer that runs the IntelliSep test using precision microfluidics and deformability cytometry. The system isolates, images, and analyzes white blood cells via ultra-high resolution imaging, computer vision, and machine learning. Requires 4 sq ft of bench space, no calibration, no vacuum or plumbing, and integrates with hospital middleware via Ethernet connection to the LIS.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Inflammatix is a direct host-response diagnostics peer developing rapid blood-based immune-transcriptional tests (HostDx) for acute infection and sepsis. It targets the same unmet need as IntelliSep—an ED-friendly, pathogen-agnostic sepsis rule-out—and competes head-to-head for hospital lab adoption.

TypeDirect peer
Description

T2 Biosystems is a direct competitor in rapid sepsis diagnostics with FDA-cleared T2Bacteria and T2Candida panels run on the T2Dx instrument. Like Cytovale, it offers hospital-lab rapid diagnostics for bloodstream infections and competes for the same ED/ICU sepsis decision point.

3MeMed Diagnostics
TypeDirect peer
Description

MeMed is a direct host-response diagnostic peer with FDA-cleared MeMed BV (bacterial vs. viral) and developing immune-based tests. It uses host immune signatures to differentiate infection etiologies at the point of care, sharing IntelliSep's 'read the immune response, not the pathogen' approach.

TypeEmerging player
Description

Prenosis is an emerging AI-driven sepsis diagnostics company, with FDA-authorized InSight platform combining EHR data and biomarkers to predict sepsis. It overlaps with IntelliSep's ED sepsis decision support use case, though it is software/EHR-based rather than a lab analyzer.

TypeDirect peer
Description

Accelerate Diagnostics provides rapid antimicrobial susceptibility testing (AST) and identification directly from positive blood cultures via the Pheno system. It addresses the same bloodstream infection/sepsis clinical pathway as Cytovale, though at a later step in the diagnostic workflow.

TypeBroad incumbent
Description

bioMérieux is a broad incumbent in clinical microbiology and sepsis diagnostics (BACT/ALERT blood culture, VITEK MS, BIOFIRE Blood Culture Identification panels). It competes in the same hospital lab sepsis workflow and represents the established standard against which IntelliSep must displace or layer.

TypeBroad incumbent
Description

Roche Diagnostics is a broad incumbent offering the cobas platform and sepsis-relevant biomarkers (procalcitonin, lactate). It is referenced in Cytovale's own materials as a comparator and represents the large, entrenched diagnostic infrastructure that IntelliSep must integrate with or differentiate against in U.S. hospital labs.

8Beckman Coulter (Danaher)
TypeBroad incumbent
Description

Beckman Coulter is a broad incumbent in hospital clinical chemistry, immunoassay, and hematology diagnostics, including sepsis-related biomarkers run on the DxH and Access platforms. It competes for the same hospital lab budget and workflow integration as Cytovale's IntelliSep on the Cytovale System.

9Abbott Diagnostics
TypeBroad incumbent
Description

Abbott Diagnostics is a broad incumbent in point-of-care and central-lab diagnostics, including the i-STAT platform commonly used in EDs for lactate and other sepsis-relevant markers. It is referenced in Cytovale's content marketing as a comparator and competes for the same ED sepsis triage workflow.

TypeBroad incumbent
Description

QuidelOrtho is a broad incumbent in clinical diagnostics, including rapid immunoassays and Triage products used in hospital and point-of-care settings. It competes for hospital lab and ED testing share, with overlap in the rapid infectious-disease and biomarker testing space where IntelliSep is deployed.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors15 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CytoVale

Sepsis Diagnosticscytovale.com

CytoVale is a medical technology company that developed IntelliSep, an FDA-cleared ~8-minute host-response sepsis diagnostic on its proprietary deformability cytometry analyzer, sold through enterprise field sales to U.S. hospital emergency departments and clinical laboratories.

What CytoVale does

CytoVale is a South San Francisco-based medical technology company that develops host-response diagnostics for early detection of immune-mediated diseases, with its commercial focus on sepsis. The company was founded in 2013 and originated in academic research dating to 2007. Its core offering is the IntelliSep Sepsis Test — an FDA 510(k)-cleared in vitro diagnostic that risk-stratifies adult emergency department patients with suspected infection for probability of sepsis with organ dysfunction within three days — paired with the Cytovale System benchtop analyzer.

The IntelliSep test runs on proprietary deformability cytometry technology: a label-free approach in which a standard 100µL blood sample is processed through microfluidic channels, individual white blood cells are interrogated by ultra-high-resolution imaging and computer vision at hundreds of thousands of frames per second, and proprietary machine-learning models translate measured biomechanical features (size, deformability, stiffness, elongation, granularity, nuclear mechanics) into an IntelliSep Index score between 0.1 and 10.0, stratified into three risk bands. Results are delivered in approximately 8 minutes, with a reported 97.5-98% negative predictive value for ruling out sepsis, and the system integrates with existing hospital laboratory workflows via Ethernet to the LIS with no internet connectivity required. Real-world implementations have reported mortality reductions of 19-42% and material improvements in ED throughput and blood culture stewardship.

CytoVale sells through a direct enterprise field-sales motion targeting U.S. hospital emergency departments and laboratories, using a structured protocolized implementation program of discovery, implementation, and reassessment. Revenue is generated through placement of the Cytovale System analyzer and recurring sales of IntelliSep test cartridges (single-use), QC kits, and reagents. The company is privately held, backed primarily by Norwest Venture Partners (lead in both Series C and Series D), Sands Capital, Global Health Investment Corporation, and Breakout Ventures, with total disclosed funding of approximately $184 million across Series C ($84M, November 2023) and Series D ($100M, October 2024).

CytoVale firmographics

Firmographics
Name
CytoVale
Legal name
Cytovale, Inc.
Website
https://cytovale.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
101–250 employees
Short description
CytoVale is a medical technology company that developed IntelliSep, an FDA-cleared ~8-minute host-response sepsis diagnostic on its proprietary deformability cytometry analyzer, sold through enterprise field sales to U.S. hospital emergency departments and clinical laboratories.
Ownership category
akta.pro rank

CytoVale industry classification

Industry
Product category
Sepsis Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAEAF
Microbiology & Infectious Disease Testing (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Sepsis diagnostic test
  • Rapid sepsis detection
  • Host response diagnostics
  • Emergency department diagnostics
  • Deformability cytometry analyzer

Where CytoVale is headquartered

Location

Headquarters

HQ city
South San Francisco
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CytoVale business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations, Infrastructure

Revenue model

  1. IntelliSep Sepsis Test Kits and Reagents: Cytovale generates revenue through the sale of its IntelliSep test cartridges (single-use), QC kits, and related reagents to hospital laboratories. The test uses 100µL from a standard purple-top K2 EDTA blood collection tube. Reagent and consumable sales are recurring as hospitals perform tests on patients presenting to EDs with suspected sepsis.
  2. Cytovale System Placement: The company places its Cytovale System analyzer in hospital laboratories. Revenue is generated through associated consumables and reagents consumed with each test. The system is provided as part of the commercial relationship with health systems implementing IntelliSep.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

CytoVale product offering

Product offering

Core offering

Cytovale develops and sells IntelliSep, an FDA-cleared in vitro diagnostic test that runs on the proprietary Cytovale System benchtop analyzer to risk-stratify adult emergency department patients with signs of infection based on probability of sepsis within 3 days, delivering results in approximately 8 minutes using deformability cytometry. Revenue is generated through placement of the Cytovale System analyzer in hospital laboratories and recurring sales of IntelliSep single-use test cartridges and reagents to U.S. hospitals and health systems.

Product overview

CytoVale offers a unified portfolio centered on the IntelliSep sepsis diagnostic test and the Cytovale System medical device. The Cytovale System is the hardware platform that runs the IntelliSep test by isolating, imaging, and analyzing white blood cells via deformability cytometry, computer vision, and machine learning. IntelliSep is the single FDA-cleared in vitro diagnostic application that generates a sepsis probability score (0.1–10.0) stratified into three risk bands in approximately 8 minutes from a 100µL blood sample. IntelliSep operates exclusively on the Cytovale System, making it a tightly coupled platform-and-assay offering rather than a modular add-on architecture.

Differentiator

Problem solved

Functional benefit

Products and services

  • IntelliSep Sepsis Test An FDA-cleared in vitro diagnostic test that risk-stratifies adult emergency department patients with signs and symptoms of infection based on probability of developing sepsis with organ dysfunction within 3 days. Delivers results in approximately 8 minutes using deformability cytometry to analyze biophysical properties of white blood cells, generating a score from 0.1-10.0 stratified into three discrete bands indicating probability of sepsis.
  • Cytovale System Analyzer A benchtop laboratory analyzer that runs the IntelliSep test using precision microfluidics and deformability cytometry. The system isolates, images, and analyzes white blood cells via ultra-high resolution imaging, computer vision, and machine learning. Requires 4 sq ft of bench space, no calibration, no vacuum or plumbing, and integrates with hospital middleware via Ethernet connection to the LIS.

Quantifiable outcome

  • 39% relative risk reduction in 30-day sepsis-associated mortality
  • +11 more outcomes

Companies that use CytoVale

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles3 records

CytoVale technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

CytoVale partnerships and signals

Strategic signal

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

CytoVale competitors and assessment

Company assessment

Direct peers

  • Inflammatix: Inflammatix is a direct host-response diagnostics peer developing rapid blood-based immune-transcriptional tests (HostDx) for acute infection and sepsis. It targets the same unmet need as IntelliSep—an ED-friendly, pathogen-agnostic sepsis rule-out—and competes head-to-head for hospital lab adoption.
  • T2 Biosystems: T2 Biosystems is a direct competitor in rapid sepsis diagnostics with FDA-cleared T2Bacteria and T2Candida panels run on the T2Dx instrument. Like Cytovale, it offers hospital-lab rapid diagnostics for bloodstream infections and competes for the same ED/ICU sepsis decision point.
  • MeMed Diagnostics: MeMed is a direct host-response diagnostic peer with FDA-cleared MeMed BV (bacterial vs. viral) and developing immune-based tests. It uses host immune signatures to differentiate infection etiologies at the point of care, sharing IntelliSep's 'read the immune response, not the pathogen' approach.
  • Accelerate Diagnostics: Accelerate Diagnostics provides rapid antimicrobial susceptibility testing (AST) and identification directly from positive blood cultures via the Pheno system. It addresses the same bloodstream infection/sepsis clinical pathway as Cytovale, though at a later step in the diagnostic workflow.

Emerging players

  • Prenosis (formerly Dascena): Prenosis is an emerging AI-driven sepsis diagnostics company, with FDA-authorized InSight platform combining EHR data and biomarkers to predict sepsis. It overlaps with IntelliSep's ED sepsis decision support use case, though it is software/EHR-based rather than a lab analyzer.

Broad incumbents

  • bioMérieux: bioMérieux is a broad incumbent in clinical microbiology and sepsis diagnostics (BACT/ALERT blood culture, VITEK MS, BIOFIRE Blood Culture Identification panels). It competes in the same hospital lab sepsis workflow and represents the established standard against which IntelliSep must displace or layer.
  • Roche Diagnostics: Roche Diagnostics is a broad incumbent offering the cobas platform and sepsis-relevant biomarkers (procalcitonin, lactate). It is referenced in Cytovale's own materials as a comparator and represents the large, entrenched diagnostic infrastructure that IntelliSep must integrate with or differentiate against in U.S. hospital labs.
  • Beckman Coulter (Danaher): Beckman Coulter is a broad incumbent in hospital clinical chemistry, immunoassay, and hematology diagnostics, including sepsis-related biomarkers run on the DxH and Access platforms. It competes for the same hospital lab budget and workflow integration as Cytovale's IntelliSep on the Cytovale System.
  • Abbott Diagnostics: Abbott Diagnostics is a broad incumbent in point-of-care and central-lab diagnostics, including the i-STAT platform commonly used in EDs for lactate and other sepsis-relevant markers. It is referenced in Cytovale's content marketing as a comparator and competes for the same ED sepsis triage workflow.
  • QuidelOrtho: QuidelOrtho is a broad incumbent in clinical diagnostics, including rapid immunoassays and Triage products used in hospital and point-of-care settings. It competes for hospital lab and ED testing share, with overlap in the rapid infectious-disease and biomarker testing space where IntelliSep is deployed.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

CytoVale social profiles

Digital presence

CytoVale compliance and trust

Trust signal

Compliance3 records

CytoVale financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CytoVale leadership team

Management profile

Number of profiles

Profiles14 records

CytoVale funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CytoVale M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CytoVale

What does CytoVale do?

Cytovale develops and sells IntelliSep, an FDA-cleared in vitro diagnostic test that runs on the proprietary Cytovale System benchtop analyzer to risk-stratify adult emergency department patients with signs of infection based on probability of sepsis within 3 days, delivering results in approximately 8 minutes using deformability cytometry. Revenue is generated through placement of the Cytovale System analyzer in hospital laboratories and recurring sales of IntelliSep single-use test cartridges and reagents to U.S. hospitals and health systems.

Is CytoVale a public or private company?

CytoVale is a private company. It is classified as venture growth investor backed and is currently operating.

When was CytoVale founded?

CytoVale was founded in 2013. It employs 101 to 250 people.

Where is CytoVale based?

CytoVale is headquartered in South San Francisco, United States, in the North America region.

How does CytoVale make money?

Two revenue lines are on record. IntelliSep Sepsis Test Kits and Reagents are the primary driver. The others are cytovale System Placement.

Who are CytoVale's main competitors?

Direct peers on record are Inflammatix, T2 Biosystems, MeMed Diagnostics and Accelerate Diagnostics. Prenosis (formerly Dascena) is listed as an emerging player. Broad incumbents are bioMérieux, Roche Diagnostics, Beckman Coulter (Danaher), Abbott Diagnostics and QuidelOrtho.

Does CytoVale have an API?

No public API is recorded for CytoVale.

What industry is CytoVale in?

CytoVale's product category is Sepsis Diagnostics. Its primary akta.pro industry code is HLAGADAH, Cell-Based & Potency Assays (Bioassays), with a secondary code of HLAGAEAF, Microbiology & Infectious Disease Testing (Trial Support). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™The sepsis diagnostics market is projected to grow from $0.83 billion in 2026 to $1.22 billion by 2031, a 7.9% CAGR. North America held the largest regional share at 43.2% in 2025, and assays & reagent kits led the product segment. Growth is driven by rising sepsis incidence and demand for rapid diagnostics.Contagion LiveIntelliSep Becomes First Sepsis Diagnostic Tool to Receive FDA ClearanceCytovale announced that its IntelliSep diagnostic tool has received 510(k) clearance from the US Food and Drug Administration, becoming the first sepsis diagnostic test to gain such approval. The FDA-cleared device is designed to identify sepsis in emergency department patients within 10 minutes by analyzing immune cell morphology. This regulatory milestone allows clinicians to rapidly classify patients based on sepsis probability to facilitate earlier treatment.Baton Rouge Business ReportBusiness Report’s Excellence in Healthcare Awards honor the region’s top leadersFMOL Health, Our Lady of the Lake, and biotech Cytovale were honored in the Achievement in Innovation category at the 2026 Excellence in Healthcare Awards. The recognition is for the research and development of IntelliSep, the nation's first FDA-approved rapid sepsis detection test for emergency rooms.PR NewswireCytovale Appoints Eric Khairy as Chief Marketing OfficerCytovale, a San Francisco-based commercial-stage medical diagnostics company, appointed Eric Khairy as Chief Marketing Officer to lead global marketing strategy and drive adoption of its IntelliSep rapid sepsis test. Khairy brings over two decades of MedTech experience, having previously helped scale Inari Medical from $6 million to $600 million in annual revenue over seven years, through an IPO and subsequent $4.9 billion acquisition by Stryker. The IntelliSep test delivers sepsis risk assessment results in approximately eight minutes and has already been used on over 65,000 patients.PR NewswirePeer-Reviewed Study Shows IntelliSep Influences ED Physicians' Sepsis Diagnostic DecisionsA peer-reviewed study published in JACEP Open evaluated Cytovale's IntelliSep sepsis diagnostic tool among 52 emergency department physicians across four U.S. hospitals, finding that IntelliSep results changed or reinforced diagnostic decisions in 86% of 1,040 case evaluations. Physicians using IntelliSep showed a 19% relative increase in diagnostic confidence (from 53.1% to 63.1%) and improved accuracy in identifying and ruling out sepsis compared to standard clinical data alone. The study provides additional validation of IntelliSep's clinical usability and complements previously reported real-world implementation data on patient outcomes following adoption.PR NewswireMulticenter Study Shows Reproducible Clinical and Operational Gains Following Expansion of IntelliSep Sepsis Test Across Health SystemCytovale announced new multicenter real-world data showing its FDA-cleared IntelliSep rapid sepsis diagnostic successfully replicated earlier clinical and operational improvements when expanded across four additional hospitals within Franciscan Missionaries of Our Lady Health system. The one-year pre- and post-implementation analysis of more than 34,000 emergency department patients with suspected infection demonstrated a 19% relative reduction in sepsis mortality, a 22% reduction in mortality among patients initially suspected of sepsis who were ultimately not septic, a 20% increase in ED discharges, and a 30% decrease in blood culture utilization. The findings, presented at the SCCM 2026 Critical Care Congress, suggest the test can drive repeatable, meaningful clinical and operational improvements across diverse hospital settings from community hospitals to tertiary care centers.PR NewswireCytovale's IntelliSep® Named Modern Healthcare's Best in Business for Second Consecutive YearCytovale announced that its IntelliSep rapid sepsis test was recognized by Modern Healthcare as a Best in Business of 2025 winner in the medical technology category for the second consecutive year. The test delivers results in eight minutes and has been used to evaluate more than 70,000 patients across multiple health systems, with hospitals reporting a 39% reduction in sepsis mortality rates and an 80% decrease in Code Sepsis alerts. The award reflects growing recognition that sepsis requires a different diagnostic approach, according to Cytovale Co-founder and CEO Ajay Shah.IdseIntelliSep rapid sepsis diagnostic testA study presented at the IHI Forum 2025 revealed that patients with suspected sepsis tested using Cytovale's IntelliSep diagnostic tool experienced a 42% lower mortality rate and shorter hospital stays compared to untested patients. The research, conducted at Froedtert Hospital involving over 6,000 emergency department patients, demonstrated that the eight-minute test significantly improved clinical decision-making and patient outcomes. Consequently, the health network is expanding the adoption of the test across its system.PR NewswireRapid Sepsis Test Enables Hospital to Reduce Mortality by 42% and Shorten Hospital Stay by Two Days, According to Academic Medical Center StudyA new study from Froedtert Hospital in Milwaukee evaluated 6,040 emergency department patients with suspected infection between August 2024 and May 2025, finding that those tested with Cytovale's IntelliSep rapid sepsis diagnostic had 42% lower mortality and spent approximately two fewer days in the hospital compared with untested patients. The IntelliSep test delivers results in eight minutes by assessing immune dysregulation, enabling clinicians to risk stratify patients at triage and make faster, more informed decisions about sepsis diagnosis. The Froedtert & the Medical College of Wisconsin health network is now expanding adoption of IntelliSep across its health system based on these results.PR NewswireNew Data Reveals Path to SEP-1 Success Includes Early Sepsis Risk StratificationA new study presented at the American College of Emergency Physicians conference reveals that Our Lady of the Lake Regional Medical Center in Baton Rouge achieved a 28.9% relative increase in SEP-1 quality metric performance over six months by integrating Cytovale's IntelliSep rapid sepsis diagnostic test into its emergency department protocol, rising from 61.2% compliance in July 2024 to 78.9% in December 2024. The study assessed 598 patients discharged with sepsis ICD-10 codes and demonstrated that the FDA-cleared host response test, which provides sepsis risk assessment within approximately eight minutes using a standard blood draw, enabled better patient stratification and improved documentation. Researchers suggest this approach could serve as a roadmap for hospitals nationwide seeking to boost compliance with the CMS SEP-1 measure while reducing overtreatment and improving patient-centered care.